(Stat News) An array of cancers — colorectal chief among them — are striking people younger than 50 at higher rates than in previous decades, prompting new screening guidelines, new research, and growing concern.
According to KFF, 80% of voters want lower drug prices. The Inflation Reduction Act was the first step, allowing the government to negotiate drug prices for Medicare. How has the drug industry responded? With contempt for the general public and trying to shift blame.
Pharmacy benefit managers (PBMs) and pharmaceutical companies have been locked in a battle over the cost of prescription drugs for years. PBMs, third-party companies that administer prescription drug benefits for health insurers, argue that they are working to reduce drug costs for patients. Pharmaceutical companies, conversely, say that PBMs are using their market power to extract excessive rebates from drugmakers, which are passed on to patients through higher prices.
The worst words in healthcare are “a private equity firm has acquired us.” Private equity firms make money by buying, gutting, and selling companies. Companies bought by private equity firms are far more likely to go bankrupt than companies that aren’t and they are killing patients in the process.
More than 18 weight loss drugs are in development because drug companies know that the market is worth billions of dollars even though insurance companies are still debating their coverage for weight loss. It’s going to be a knockout, drag-down battle.
Oncologists are experts in evaluating the nature of cancer, how it’s treated, and the side effects of the treatments used. As cancer treatments continue to improve, oncologists constantly assess their patients’ best options but do patients always listen?